Rapport Therapeutics Q3 EPS $(0.84) Beats $(1.19) Estimate
Benzinga Newsdesk 16 hours ago
NewsEarningsEarnings Beats
Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(1.19) by 29.41 percent. This is a 18.31 percent decrease over losses of $(0.71) per share
Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(1.19) by 29.41 percent. This is a 18.31 percent decrease over losses of $(0.71) per share from the same period last year.